Key takeaway: MedPlus Health Services Limited provided an investor presentation detailing its un-audited financial results for the quarter ended June 30, 2026. The presentation highlighted a revenue of ₹18,796 million, marking a 21.8% year-over-year increase. The gross margin was reported at ₹4,603 million, with a gross margin percentage of 24.5%, which was lower compared to the previous year. The company added 146 net stores, bringing the total to 5,476. The operating EBITDA was ₹651 million, reflecting a decrease from the previous quarter. The presentation emphasized the company's strong cluster-based network, which supports its omni-channel strategy and allows for rapid delivery services. Management outlined key growth pillars, including expanding existing clusters, leveraging technology for omni-channel offerings, and increasing the share of private label products. The document also included a snapshot of the income statement and balance sheet, indicating a focus on cash management and capital productivity.

Key takeaway: MedPlus Health Services Limited reported a revenue growth of 21.8% year-over-year, reaching ₹18,796 million for Q1 FY27. The company added 146 new stores during the quarter, including 131 franchisees. However, the gross margin decreased by 160 basis points to 24.5%, and operating EBITDA fell from ₹728 million in Q1 FY26 to ₹651 million in Q1 FY27, resulting in a decline in operating EBITDA margin from 4.7% to 3.5%. The document noted that revenue achievement was at 99.0% of the annual operating plan, while operating EBITDA achieved 81.6%. The presentation also highlighted a decrease in gross margin due to a lower sales mix of private label products and lower margins in the franchisee business. The company operates a network of 5,476 pharmacies across 850+ cities.

Key takeaway: MedPlus Health Services Limited held its Q4 FY26 Earnings Conference Call on May 21, 2026, to discuss financial results for the quarter and the fiscal year ended March 31, 2026. Management reported a net addition of 218 stores during the quarter, with plans to open 800 new stores in FY27. The company achieved consolidated revenue of INR 18,644 million for the quarter, with an operating EBITDA of INR 1,076 million. Private label sales constituted 22% of total revenues, with pharmacy operations growing by 23.4% year-on-year. Management noted that stores older than 12 months contributed significantly to revenue, with a store-level EBITDA margin of 13.1%. The discussion included updates on working capital, inventory levels, and the performance of the diagnostics segment. Management emphasized a balanced growth strategy between branded and private label products, while also addressing questions regarding store closures and the franchisee model.

Key takeaway: MedPlus Health Services Limited provided an investor presentation detailing its audited financial results for the quarter and financial year ended March 31, 2026. The presentation highlighted a revenue of ₹68,925 million for FY2026, marking a 12.3% increase from FY2025, with a gross margin of ₹18,079 million. The company reported 618 net store additions, with a total of 5,330 stores as of March 31, 2026. For Q4 FY2026, revenue reached ₹18,644 million, a 23.5% year-over-year increase. The gross margin for the quarter was ₹4,934 million, with a 26.5% gross margin percentage. The presentation emphasized the company's strong cluster-based network and plans for growth in existing and new markets, leveraging its omni-channel capabilities and expanding its private label offerings. MedPlus also reported an operating cash flow of ₹917 million for the quarter.

Key takeaway: MedPlus Health Services Limited held its Q3 FY '26 Earnings Conference Call on February 2, 2026, to discuss financial results for the quarter ended December 31, 2025. Management reported the opening of 228 new stores and a net addition of 182 stores during the quarter, bringing the total to 5,112 stores. Revenue for the quarter reached 18,061 million, with a 15.6% year-on-year growth in pharmacy operations. The operating EBITDA was reported at 96.8 crores, reflecting a margin of 5.4%. Private label sales constituted 22.2% of total revenues, with significant growth in both private label pharma and non-pharma segments. Management noted improvements in store-level EBITDA margins and a reduction in net working capital days. The call included discussions on incentive structure changes, inventory management, and ongoing expansion strategies, with management emphasizing a focus on enhancing store performance and product offerings.